Cibus, Inc. (CBUS) 10-Year Financial Performance & Capital Metrics

CBUS • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutCibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.Show more

Revenue $4M +134.6%
EBITDA -$252M +19.9%
Net Income -$251M +6.1%
EPS (Diluted) -10.83 +58.3%
Gross Margin 100% +27.8%
EBITDA Margin -5901.85% +65.9%
Operating Margin -6062.79% +65.5%
Net Margin -5898.36% +60.0%
ROE -115.28% +25.6%
ROIC -86.15% +37.3%
Debt/Equity 0.37 +409.6%
Interest Coverage -7.56 +55.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.4x book value

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 10.2% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-10.19%

3Y-45.26%

TTM-8.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.3%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.02%

ROCE

10Y Avg-61.35%

5Y Avg-78.41%

3Y Avg-87.36%

Latest-60.57%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.27M	399K	508K	236K	7.3M	23.85M	25.99M	157K	1.82M	4.26M
Revenue Growth %	-	-0.69%	0.27%	-0.54%	29.92%	2.27%	0.09%	-0.99%	10.57%	1.35%
Cost of Goods Sold+	751K	200K	551K	1.08M	9.28M	35.13M	28.56M	1.53M	395K	0
COGS % of Revenue	0.59%	0.5%	1.08%	4.58%	1.27%	1.47%	1.1%	9.77%	0.22%	-
Gross Profit+	521K	199K	-43K	-845K	-1.98M	-11.28M	-2.57M	-1.38M	1.42M	4.26M
Gross Margin %	0.41%	0.5%	-0.08%	-3.58%	-0.27%	-0.47%	-0.1%	-8.77%	0.78%	1%
Gross Profit Growth %	-	-0.62%	-1.22%	-18.65%	-1.35%	-4.68%	0.77%	0.46%	2.03%	2%
Operating Expenses+	6.33M	12.31M	26.3M	28.35M	37.69M	32.56M	26.76M	20.99M	320.31M	262.66M
OpEx % of Revenue	4.98%	30.85%	51.77%	120.13%	5.17%	1.36%	1.03%	133.71%	176.28%	61.63%
Selling, General & Admin	3.57M	6.67M	14.74M	18.5M	24.14M	20.79M	15.38M	9.44M	28.91M	30.8M
SG&A % of Revenue	2.81%	16.72%	29.02%	78.41%	3.31%	0.87%	0.59%	60.13%	15.91%	7.23%
Research & Development	2.77M	5.64M	11.56M	9.85M	12.21M	11.08M	11.34M	11.55M	42.37M	50.43M
R&D % of Revenue	2.17%	14.13%	22.75%	41.72%	1.67%	0.46%	0.44%	73.59%	23.32%	11.83%
Other Operating Expenses	0	0	0	0	1.34M	685K	19K	0	249.02M	181.43M
Operating Income+	-5.81M	-12.11M	-25.79M	-28.11M	-39.67M	-43.83M	-29.33M	-22.37M	-318.88M	-258.4M
Operating Margin %	-4.57%	-30.35%	-50.77%	-119.13%	-5.44%	-1.84%	-1.13%	-142.48%	-175.5%	-60.63%
Operating Income Growth %	-	-1.08%	-1.13%	-0.09%	-0.41%	-0.1%	0.33%	0.24%	-13.25%	0.19%
EBITDA+	-5.67M	-11.76M	-25.24M	-27.03M	-38.07M	-41.96M	-26.99M	-20.84M	-314.19M	-251.54M
EBITDA Margin %	-4.46%	-29.48%	-49.68%	-114.55%	-5.22%	-1.76%	-1.04%	-132.71%	-172.92%	-59.02%
EBITDA Growth %	-	-1.08%	-1.15%	-0.07%	-0.41%	-0.1%	0.36%	0.23%	-14.08%	0.2%
D&A (Non-Cash Add-back)	147K	345K	551K	1.08M	1.61M	1.87M	2.34M	1.53M	4.69M	6.86M
EBIT	-5.63M	-12.08M	-25.72M	-26.64M	-38.12M	-43.4M	-27.77M	-16.74M	-318.75M	-248.49M
Net Interest Income+	-261K	-5K	-1K	264K	110K	-878K	-1.41M	-27K	-18.36M	-33.56M
Interest Income	0	0	0	1.52M	1.6M	557K	17K	60K	527K	631K
Interest Expense	261K	5K	1K	1.26M	1.49M	1.44M	1.43M	87K	18.89M	34.19M
Other Income/Expense	-75K	23K	-191K	218K	61K	-1M	133K	5.48M	-18.76M	-24.29M
Pretax Income+	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-337.64M	-282.68M
Pretax Margin %	-4.63%	-30.29%	-51.14%	-118.21%	-5.43%	-1.88%	-1.12%	-107.59%	-185.82%	-66.33%
Income Tax+	0	5K	1K	0	0	0	0	0	-4K	29K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.79%	0.89%
Net Income+	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-267.63M	-251.39M
Net Margin %	-4.63%	-30.29%	-51.14%	-118.21%	-5.43%	-1.88%	-1.12%	-107.59%	-147.29%	-58.98%
Net Income Growth %	-	-1.05%	-1.15%	-0.07%	-0.42%	-0.13%	0.35%	0.42%	-14.84%	0.06%
Net Income (Continuing)	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-337.64M	-282.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	44.82M	5.67M
EPS (Diluted)+	-11.07	-22.72	-56.10	-45.46	-60.37	-66.16	-0.05	-0.03	-25.95	-10.83
EPS Growth %	-	-1.05%	-1.47%	0.19%	-0.33%	-0.1%	1%	0.42%	-887.7%	0.58%
EPS (Basic)	-11.07	-22.72	-56.10	-45.46	-60.37	-66.16	-0.05	-0.03	-25.95	-10.83
Diluted Shares Outstanding	532M	532M	463.07M	613.67M	656.11M	677.65M	578.47M	578.47M	10.31M	23.22M
Basic Shares Outstanding	532M	532M	463.07M	613.67M	656.11M	677.65M	578.47M	578.47M	10.31M	23.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.03M	5.46M	57.46M	95.52M	63.52M	39.59M	15.18M	4.13M	35.22M	16.95M
Cash & Short-Term Investments	24.69M	5.03M	56.66M	93.79M	58.61M	29M	13.82M	3.43M	32.7M	14.43M
Cash Only	24.69M	5.03M	56.66M	93.79M	58.61M	17.3M	13.82M	3.43M	32.7M	14.43M
Short-Term Investments	0	0	0	0	0	11.7M	0	0	0	0
Accounts Receivable	334K	157K	167K	46K	1.12M	4.89M	0	0	530K	1.04M
Days Sales Outstanding	95.84	143.62	119.99	71.14	56.13	74.79	-	-	106.47	89.15
Inventory	0	0	0	1.31M	2.59M	1.38M	0	0	0	0
Days Inventory Outstanding	-	-	-	444.01	102.03	14.37	-	-	-	-
Other Current Assets	0	0	138K	67K	388K	393K	499K	705K	1.99M	1.47M
Total Non-Current Assets+	963K	11.16M	14.71M	23.27M	24.58M	23.74M	22.01M	18.29M	509.19M	333.12M
Property, Plant & Equipment	915K	10.99M	14.35M	21.85M	23.21M	22.86M	21.73M	18.13M	37.46M	44.69M
Fixed Asset Turnover	1.39x	0.04x	0.04x	0.01x	0.31x	1.04x	1.20x	0.01x	0.05x	0.10x
Goodwill	0	0	0	0	0	0	0	0	434.9M	253.47M
Intangible Assets	0	0	0	0	0	0	0	158K	35.41M	33.58M
Long-Term Investments	0	0	0	1.11M	0	0	0	0	0	0
Other Non-Current Assets	48K	164K	357K	306K	1.36M	877K	282K	0	1.42M	1.39M
Total Assets+	26M	16.62M	72.17M	118.79M	88.1M	63.33M	37.19M	22.42M	544.41M	350.07M
Asset Turnover	0.05x	0.02x	0.01x	0.00x	0.08x	0.38x	0.70x	0.01x	0.00x	0.01x
Asset Growth %	-	-0.36%	3.34%	0.65%	-0.26%	-0.28%	-0.41%	-0.4%	23.28%	-0.36%
Total Current Liabilities+	1.04M	2.87M	4.25M	7M	7.2M	6.95M	4.85M	1.66M	21.32M	19.88M
Accounts Payable	304K	357K	1.02M	818K	1.08M	929K	1.26M	340K	6.13M	5.96M
Days Payables Outstanding	147.75	651.52	677.67	276.2	42.36	9.65	16.1	80.9	5.66K	-
Short-Term Debt	0	0	1.35M	0	0	0	0	0	833K	436K
Deferred Revenue (Current)	182K	101K	43K	248K	0	0	0	107K	1000K	932K
Other Current Liabilities	0	2.08M	78K	1.77M	2.24M	2M	2.71M	403K	5.29M	5.87M
Current Ratio	24.16x	1.91x	13.51x	13.64x	8.83x	5.70x	3.13x	2.49x	1.65x	0.85x
Quick Ratio	24.16x	1.91x	13.51x	13.45x	8.47x	5.50x	3.13x	2.49x	1.65x	0.85x
Cash Conversion Cycle	-	-	-	238.96	115.8	79.5	-	-	-	-
Total Non-Current Liabilities+	702K	639K	10.44M	18.39M	18.39M	19.51M	18.21M	13.53M	184.79M	232.36M
Long-Term Debt	0	0	0	0	0	1.52M	0	0	536K	226K
Capital Lease Obligations	0	0	10.15M	18.23M	18.24M	17.88M	17.51M	13.45M	17.14M	31.22M
Deferred Tax Liabilities	0	0	-10.15M	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	163K	150K	113K	702K	79K	167.12M	200.91M
Total Liabilities	1.74M	3.5M	14.69M	25.39M	25.59M	26.45M	23.06M	15.19M	206.12M	252.24M
Total Debt+	0	0	10.15M	18.48M	18.6M	19.76M	17.88M	13.91M	24.62M	36.29M
Net Debt	-24.69M	-5.03M	-46.52M	-75.31M	-40.01M	2.46M	4.05M	10.48M	-8.08M	21.85M
Debt / Equity	-	-	0.18x	0.20x	0.30x	0.54x	1.26x	1.92x	0.07x	0.37x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-22.28x	-2421.80x	-25789.00x	-22.37x	-26.63x	-30.54x	-20.50x	-257.13x	-16.88x	-7.56x
Total Equity+	24.26M	13.12M	57.48M	93.4M	62.51M	36.88M	14.13M	7.23M	338.29M	97.83M
Equity Growth %	-	-0.46%	3.38%	0.62%	-0.33%	-0.41%	-0.62%	-0.49%	45.77%	-0.71%
Book Value per Share	0.05	0.02	0.12	0.15	0.10	0.05	0.02	0.01	32.80	4.21
Total Shareholders' Equity	24.26M	13.12M	57.48M	93.4M	62.51M	36.88M	14.13M	7.23M	293.47M	92.16M
Common Stock	1K	1K	3K	3K	3K	4K	4K	5K	8K	9K
Retained Earnings	-16.48M	-28.57M	-54.55M	-82.44M	-122.06M	-166.89M	-196.09M	-212.15M	-479.78M	-731.17M
Treasury Stock	0	0	0	-230K	-1.04M	-1.04M	-1.04M	-1.04M	-1.78M	-2M
Accumulated OCI	-387K	-732K	-1.28M	-2.09M	17K	0	0	0	8K	15K
Minority Interest	0	0	0	0	0	0	0	0	44.82M	5.67M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.69M	-9.24M	-12.79M	-20.25M	-31.95M	-43.67M	-18.81M	-19.36M	-46.21M	-58.04M
Operating CF Margin %	-5.26%	-23.15%	-25.17%	-85.81%	-4.38%	-1.83%	-0.72%	-123.34%	-25.43%	-13.62%
Operating CF Growth %	-	-0.38%	-0.38%	-0.58%	-0.58%	-0.37%	0.57%	-0.03%	-1.39%	-0.26%
Net Income	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-267.63M	-282.71M
Depreciation & Amortization	147K	345K	551K	1.08M	1.61M	1.87M	2.34M	1.53M	4.69M	6.86M
Stock-Based Compensation	692K	948K	12.09M	4.38M	0	4.97M	2.09M	4M	0	10.75M
Deferred Taxes	-692K	-948K	0	0	0	0	0	0	0	0
Other Non-Cash Items	692K	948K	12.42M	11K	9.18M	0	-1.53M	-5.12M	215.76M	206.68M
Working Capital Changes	-1.64M	1.56M	552K	2.17M	-3.12M	-5.68M	7.49M	-2.88M	961K	383K
Change in Receivables	25K	107K	110K	0	-1.12M	-3.77M	4.89M	0	1.7M	-512K
Change in Inventory	192K	-162K	667K	0	-2.59M	1.21M	1.38M	0	0	0
Change in Payables	-28K	53K	665K	-193K	259K	-148K	-360K	-229K	2K	-188K
Cash from Investing+	-665K	-10.42M	-779K	-1.8M	-2.97M	-13.48M	11.2M	-1.52M	55.06M	-808K
Capital Expenditures	-665K	-10.42M	-779K	-1.85M	-2.97M	-1.79M	-497K	-1.52M	-4.32M	-808K
CapEx % of Revenue	0.52%	26.13%	1.53%	7.83%	0.41%	0.07%	0.02%	9.68%	2.38%	0.19%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	50K	0	-11.7M	11.7M	0	0	0
Cash from Financing+	31.74M	0	65.2M	60.67M	-330K	15.41M	3.74M	9.99M	20.32M	40.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-110K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	31.85M	0	0	1.73M	-813K	-751K	-274K	-1.17M	1.76M	-2.42M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.36M	-19.66M	-13.56M	-22.1M	-34.92M	-45.46M	-19.31M	-20.88M	-50.53M	-58.85M
FCF Margin %	-5.78%	-49.28%	-26.7%	-93.64%	-4.79%	-1.91%	-0.74%	-133.02%	-27.81%	-13.81%
FCF Growth %	-	-1.67%	0.31%	-0.63%	-0.58%	-0.3%	0.58%	-0.08%	-1.42%	-0.16%
FCF per Share	-0.01	-0.04	-0.03	-0.04	-0.05	-0.07	-0.03	-0.04	-4.90	-2.53
FCF Conversion (FCF/Net Income)	1.14x	0.76x	0.49x	0.73x	0.81x	0.97x	0.64x	1.15x	0.17x	0.23x
Interest Paid	0	0	0	0	0	1.46M	1.43M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-24.28%	-64.67%	-73.6%	-36.98%	-50.82%	-90.23%	-114.49%	-158.12%	-154.91%	-115.28%
Return on Invested Capital (ROIC)	-	-237.03%	-203.03%	-145.18%	-146.63%	-106.33%	-76.49%	-93.46%	-137.48%	-86.15%
Gross Margin	40.96%	49.87%	-8.46%	-358.05%	-27.19%	-47.28%	-9.89%	-877.07%	78.26%	100%
Net Margin	-462.97%	-3029.07%	-5114.17%	-11820.76%	-542.93%	-187.98%	-112.36%	-10758.6%	-14729.06%	-5898.36%
Debt / Equity	-	-	0.18x	0.20x	0.30x	0.54x	1.26x	1.92x	0.07x	0.37x
Interest Coverage	-22.28x	-2421.80x	-25789.00x	-22.37x	-26.63x	-30.54x	-20.50x	-257.13x	-16.88x	-7.56x
FCF Conversion	1.14x	0.76x	0.49x	0.73x	0.81x	0.97x	0.64x	1.15x	0.17x	0.23x
Revenue Growth	-	-68.63%	27.32%	-53.54%	2991.53%	226.91%	8.96%	-99.4%	1057.32%	134.56%

Revenue by Segment

	2024
Reportable	4.26M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Cibus, Inc. (CBUS) reported $3.8M in revenue for fiscal year 2024. This represents a 198% increase from $1.3M in 2015.

Cibus, Inc. (CBUS) grew revenue by 134.6% over the past year. This is strong growth.

Cibus, Inc. (CBUS) reported a net loss of $118.9M for fiscal year 2024.

Dividend & Returns

Cibus, Inc. (CBUS) has a return on equity (ROE) of -115.3%. Negative ROE indicates the company is unprofitable.

Cibus, Inc. (CBUS) had negative free cash flow of $51.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cibus, Inc. (CBUS) 10-Year Financial Performance & Capital Metrics

CBUS • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $4M +134.6%
EBITDA -$252M +19.9%
Net Income -$251M +6.1%
EPS (Diluted) -10.83 +58.3%
Gross Margin 100% +27.8%
EBITDA Margin -5901.85% +65.9%
Operating Margin -6062.79% +65.5%
Net Margin -5898.36% +60.0%
ROE -115.28% +25.6%
ROIC -86.15% +37.3%
Debt/Equity 0.37 +409.6%
Interest Coverage -7.56 +55.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.4x book value

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 10.2% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-10.19%

3Y-45.26%

TTM-8.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.3%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.02%

ROCE

10Y Avg-61.35%

5Y Avg-78.41%

3Y Avg-87.36%

Latest-60.57%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.27M	399K	508K	236K	7.3M	23.85M	25.99M	157K	1.82M	4.26M
Revenue Growth %	-	-0.69%	0.27%	-0.54%	29.92%	2.27%	0.09%	-0.99%	10.57%	1.35%
Cost of Goods Sold+	751K	200K	551K	1.08M	9.28M	35.13M	28.56M	1.53M	395K	0
COGS % of Revenue	0.59%	0.5%	1.08%	4.58%	1.27%	1.47%	1.1%	9.77%	0.22%	-
Gross Profit+	521K	199K	-43K	-845K	-1.98M	-11.28M	-2.57M	-1.38M	1.42M	4.26M
Gross Margin %	0.41%	0.5%	-0.08%	-3.58%	-0.27%	-0.47%	-0.1%	-8.77%	0.78%	1%
Gross Profit Growth %	-	-0.62%	-1.22%	-18.65%	-1.35%	-4.68%	0.77%	0.46%	2.03%	2%
Operating Expenses+	6.33M	12.31M	26.3M	28.35M	37.69M	32.56M	26.76M	20.99M	320.31M	262.66M
OpEx % of Revenue	4.98%	30.85%	51.77%	120.13%	5.17%	1.36%	1.03%	133.71%	176.28%	61.63%
Selling, General & Admin	3.57M	6.67M	14.74M	18.5M	24.14M	20.79M	15.38M	9.44M	28.91M	30.8M
SG&A % of Revenue	2.81%	16.72%	29.02%	78.41%	3.31%	0.87%	0.59%	60.13%	15.91%	7.23%
Research & Development	2.77M	5.64M	11.56M	9.85M	12.21M	11.08M	11.34M	11.55M	42.37M	50.43M
R&D % of Revenue	2.17%	14.13%	22.75%	41.72%	1.67%	0.46%	0.44%	73.59%	23.32%	11.83%
Other Operating Expenses	0	0	0	0	1.34M	685K	19K	0	249.02M	181.43M
Operating Income+	-5.81M	-12.11M	-25.79M	-28.11M	-39.67M	-43.83M	-29.33M	-22.37M	-318.88M	-258.4M
Operating Margin %	-4.57%	-30.35%	-50.77%	-119.13%	-5.44%	-1.84%	-1.13%	-142.48%	-175.5%	-60.63%
Operating Income Growth %	-	-1.08%	-1.13%	-0.09%	-0.41%	-0.1%	0.33%	0.24%	-13.25%	0.19%
EBITDA+	-5.67M	-11.76M	-25.24M	-27.03M	-38.07M	-41.96M	-26.99M	-20.84M	-314.19M	-251.54M
EBITDA Margin %	-4.46%	-29.48%	-49.68%	-114.55%	-5.22%	-1.76%	-1.04%	-132.71%	-172.92%	-59.02%
EBITDA Growth %	-	-1.08%	-1.15%	-0.07%	-0.41%	-0.1%	0.36%	0.23%	-14.08%	0.2%
D&A (Non-Cash Add-back)	147K	345K	551K	1.08M	1.61M	1.87M	2.34M	1.53M	4.69M	6.86M
EBIT	-5.63M	-12.08M	-25.72M	-26.64M	-38.12M	-43.4M	-27.77M	-16.74M	-318.75M	-248.49M
Net Interest Income+	-261K	-5K	-1K	264K	110K	-878K	-1.41M	-27K	-18.36M	-33.56M
Interest Income	0	0	0	1.52M	1.6M	557K	17K	60K	527K	631K
Interest Expense	261K	5K	1K	1.26M	1.49M	1.44M	1.43M	87K	18.89M	34.19M
Other Income/Expense	-75K	23K	-191K	218K	61K	-1M	133K	5.48M	-18.76M	-24.29M
Pretax Income+	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-337.64M	-282.68M
Pretax Margin %	-4.63%	-30.29%	-51.14%	-118.21%	-5.43%	-1.88%	-1.12%	-107.59%	-185.82%	-66.33%
Income Tax+	0	5K	1K	0	0	0	0	0	-4K	29K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.79%	0.89%
Net Income+	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-267.63M	-251.39M
Net Margin %	-4.63%	-30.29%	-51.14%	-118.21%	-5.43%	-1.88%	-1.12%	-107.59%	-147.29%	-58.98%
Net Income Growth %	-	-1.05%	-1.15%	-0.07%	-0.42%	-0.13%	0.35%	0.42%	-14.84%	0.06%
Net Income (Continuing)	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-337.64M	-282.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	44.82M	5.67M
EPS (Diluted)+	-11.07	-22.72	-56.10	-45.46	-60.37	-66.16	-0.05	-0.03	-25.95	-10.83
EPS Growth %	-	-1.05%	-1.47%	0.19%	-0.33%	-0.1%	1%	0.42%	-887.7%	0.58%
EPS (Basic)	-11.07	-22.72	-56.10	-45.46	-60.37	-66.16	-0.05	-0.03	-25.95	-10.83
Diluted Shares Outstanding	532M	532M	463.07M	613.67M	656.11M	677.65M	578.47M	578.47M	10.31M	23.22M
Basic Shares Outstanding	532M	532M	463.07M	613.67M	656.11M	677.65M	578.47M	578.47M	10.31M	23.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	25.03M	5.46M	57.46M	95.52M	63.52M	39.59M	15.18M	4.13M	35.22M	16.95M
Cash & Short-Term Investments	24.69M	5.03M	56.66M	93.79M	58.61M	29M	13.82M	3.43M	32.7M	14.43M
Cash Only	24.69M	5.03M	56.66M	93.79M	58.61M	17.3M	13.82M	3.43M	32.7M	14.43M
Short-Term Investments	0	0	0	0	0	11.7M	0	0	0	0
Accounts Receivable	334K	157K	167K	46K	1.12M	4.89M	0	0	530K	1.04M
Days Sales Outstanding	95.84	143.62	119.99	71.14	56.13	74.79	-	-	106.47	89.15
Inventory	0	0	0	1.31M	2.59M	1.38M	0	0	0	0
Days Inventory Outstanding	-	-	-	444.01	102.03	14.37	-	-	-	-
Other Current Assets	0	0	138K	67K	388K	393K	499K	705K	1.99M	1.47M
Total Non-Current Assets+	963K	11.16M	14.71M	23.27M	24.58M	23.74M	22.01M	18.29M	509.19M	333.12M
Property, Plant & Equipment	915K	10.99M	14.35M	21.85M	23.21M	22.86M	21.73M	18.13M	37.46M	44.69M
Fixed Asset Turnover	1.39x	0.04x	0.04x	0.01x	0.31x	1.04x	1.20x	0.01x	0.05x	0.10x
Goodwill	0	0	0	0	0	0	0	0	434.9M	253.47M
Intangible Assets	0	0	0	0	0	0	0	158K	35.41M	33.58M
Long-Term Investments	0	0	0	1.11M	0	0	0	0	0	0
Other Non-Current Assets	48K	164K	357K	306K	1.36M	877K	282K	0	1.42M	1.39M
Total Assets+	26M	16.62M	72.17M	118.79M	88.1M	63.33M	37.19M	22.42M	544.41M	350.07M
Asset Turnover	0.05x	0.02x	0.01x	0.00x	0.08x	0.38x	0.70x	0.01x	0.00x	0.01x
Asset Growth %	-	-0.36%	3.34%	0.65%	-0.26%	-0.28%	-0.41%	-0.4%	23.28%	-0.36%
Total Current Liabilities+	1.04M	2.87M	4.25M	7M	7.2M	6.95M	4.85M	1.66M	21.32M	19.88M
Accounts Payable	304K	357K	1.02M	818K	1.08M	929K	1.26M	340K	6.13M	5.96M
Days Payables Outstanding	147.75	651.52	677.67	276.2	42.36	9.65	16.1	80.9	5.66K	-
Short-Term Debt	0	0	1.35M	0	0	0	0	0	833K	436K
Deferred Revenue (Current)	182K	101K	43K	248K	0	0	0	107K	1000K	932K
Other Current Liabilities	0	2.08M	78K	1.77M	2.24M	2M	2.71M	403K	5.29M	5.87M
Current Ratio	24.16x	1.91x	13.51x	13.64x	8.83x	5.70x	3.13x	2.49x	1.65x	0.85x
Quick Ratio	24.16x	1.91x	13.51x	13.45x	8.47x	5.50x	3.13x	2.49x	1.65x	0.85x
Cash Conversion Cycle	-	-	-	238.96	115.8	79.5	-	-	-	-
Total Non-Current Liabilities+	702K	639K	10.44M	18.39M	18.39M	19.51M	18.21M	13.53M	184.79M	232.36M
Long-Term Debt	0	0	0	0	0	1.52M	0	0	536K	226K
Capital Lease Obligations	0	0	10.15M	18.23M	18.24M	17.88M	17.51M	13.45M	17.14M	31.22M
Deferred Tax Liabilities	0	0	-10.15M	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	163K	150K	113K	702K	79K	167.12M	200.91M
Total Liabilities	1.74M	3.5M	14.69M	25.39M	25.59M	26.45M	23.06M	15.19M	206.12M	252.24M
Total Debt+	0	0	10.15M	18.48M	18.6M	19.76M	17.88M	13.91M	24.62M	36.29M
Net Debt	-24.69M	-5.03M	-46.52M	-75.31M	-40.01M	2.46M	4.05M	10.48M	-8.08M	21.85M
Debt / Equity	-	-	0.18x	0.20x	0.30x	0.54x	1.26x	1.92x	0.07x	0.37x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-22.28x	-2421.80x	-25789.00x	-22.37x	-26.63x	-30.54x	-20.50x	-257.13x	-16.88x	-7.56x
Total Equity+	24.26M	13.12M	57.48M	93.4M	62.51M	36.88M	14.13M	7.23M	338.29M	97.83M
Equity Growth %	-	-0.46%	3.38%	0.62%	-0.33%	-0.41%	-0.62%	-0.49%	45.77%	-0.71%
Book Value per Share	0.05	0.02	0.12	0.15	0.10	0.05	0.02	0.01	32.80	4.21
Total Shareholders' Equity	24.26M	13.12M	57.48M	93.4M	62.51M	36.88M	14.13M	7.23M	293.47M	92.16M
Common Stock	1K	1K	3K	3K	3K	4K	4K	5K	8K	9K
Retained Earnings	-16.48M	-28.57M	-54.55M	-82.44M	-122.06M	-166.89M	-196.09M	-212.15M	-479.78M	-731.17M
Treasury Stock	0	0	0	-230K	-1.04M	-1.04M	-1.04M	-1.04M	-1.78M	-2M
Accumulated OCI	-387K	-732K	-1.28M	-2.09M	17K	0	0	0	8K	15K
Minority Interest	0	0	0	0	0	0	0	0	44.82M	5.67M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.69M	-9.24M	-12.79M	-20.25M	-31.95M	-43.67M	-18.81M	-19.36M	-46.21M	-58.04M
Operating CF Margin %	-5.26%	-23.15%	-25.17%	-85.81%	-4.38%	-1.83%	-0.72%	-123.34%	-25.43%	-13.62%
Operating CF Growth %	-	-0.38%	-0.38%	-0.58%	-0.58%	-0.37%	0.57%	-0.03%	-1.39%	-0.26%
Net Income	-5.89M	-12.09M	-25.98M	-27.9M	-39.61M	-44.84M	-29.2M	-16.89M	-267.63M	-282.71M
Depreciation & Amortization	147K	345K	551K	1.08M	1.61M	1.87M	2.34M	1.53M	4.69M	6.86M
Stock-Based Compensation	692K	948K	12.09M	4.38M	0	4.97M	2.09M	4M	0	10.75M
Deferred Taxes	-692K	-948K	0	0	0	0	0	0	0	0
Other Non-Cash Items	692K	948K	12.42M	11K	9.18M	0	-1.53M	-5.12M	215.76M	206.68M
Working Capital Changes	-1.64M	1.56M	552K	2.17M	-3.12M	-5.68M	7.49M	-2.88M	961K	383K
Change in Receivables	25K	107K	110K	0	-1.12M	-3.77M	4.89M	0	1.7M	-512K
Change in Inventory	192K	-162K	667K	0	-2.59M	1.21M	1.38M	0	0	0
Change in Payables	-28K	53K	665K	-193K	259K	-148K	-360K	-229K	2K	-188K
Cash from Investing+	-665K	-10.42M	-779K	-1.8M	-2.97M	-13.48M	11.2M	-1.52M	55.06M	-808K
Capital Expenditures	-665K	-10.42M	-779K	-1.85M	-2.97M	-1.79M	-497K	-1.52M	-4.32M	-808K
CapEx % of Revenue	0.52%	26.13%	1.53%	7.83%	0.41%	0.07%	0.02%	9.68%	2.38%	0.19%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	50K	0	-11.7M	11.7M	0	0	0
Cash from Financing+	31.74M	0	65.2M	60.67M	-330K	15.41M	3.74M	9.99M	20.32M	40.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-110K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	31.85M	0	0	1.73M	-813K	-751K	-274K	-1.17M	1.76M	-2.42M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.36M	-19.66M	-13.56M	-22.1M	-34.92M	-45.46M	-19.31M	-20.88M	-50.53M	-58.85M
FCF Margin %	-5.78%	-49.28%	-26.7%	-93.64%	-4.79%	-1.91%	-0.74%	-133.02%	-27.81%	-13.81%
FCF Growth %	-	-1.67%	0.31%	-0.63%	-0.58%	-0.3%	0.58%	-0.08%	-1.42%	-0.16%
FCF per Share	-0.01	-0.04	-0.03	-0.04	-0.05	-0.07	-0.03	-0.04	-4.90	-2.53
FCF Conversion (FCF/Net Income)	1.14x	0.76x	0.49x	0.73x	0.81x	0.97x	0.64x	1.15x	0.17x	0.23x
Interest Paid	0	0	0	0	0	1.46M	1.43M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-24.28%	-64.67%	-73.6%	-36.98%	-50.82%	-90.23%	-114.49%	-158.12%	-154.91%	-115.28%
Return on Invested Capital (ROIC)	-	-237.03%	-203.03%	-145.18%	-146.63%	-106.33%	-76.49%	-93.46%	-137.48%	-86.15%
Gross Margin	40.96%	49.87%	-8.46%	-358.05%	-27.19%	-47.28%	-9.89%	-877.07%	78.26%	100%
Net Margin	-462.97%	-3029.07%	-5114.17%	-11820.76%	-542.93%	-187.98%	-112.36%	-10758.6%	-14729.06%	-5898.36%
Debt / Equity	-	-	0.18x	0.20x	0.30x	0.54x	1.26x	1.92x	0.07x	0.37x
Interest Coverage	-22.28x	-2421.80x	-25789.00x	-22.37x	-26.63x	-30.54x	-20.50x	-257.13x	-16.88x	-7.56x
FCF Conversion	1.14x	0.76x	0.49x	0.73x	0.81x	0.97x	0.64x	1.15x	0.17x	0.23x
Revenue Growth	-	-68.63%	27.32%	-53.54%	2991.53%	226.91%	8.96%	-99.4%	1057.32%	134.56%

Revenue by Segment

	2024
Reportable	4.26M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Cibus, Inc. (CBUS) reported $3.8M in revenue for fiscal year 2024. This represents a 198% increase from $1.3M in 2015.

Cibus, Inc. (CBUS) grew revenue by 134.6% over the past year. This is strong growth.

Cibus, Inc. (CBUS) reported a net loss of $118.9M for fiscal year 2024.

Dividend & Returns

Cibus, Inc. (CBUS) has a return on equity (ROE) of -115.3%. Negative ROE indicates the company is unprofitable.

Cibus, Inc. (CBUS) had negative free cash flow of $51.7M in fiscal year 2024, likely due to heavy capital investments.